Structural biology and molecular modeling market seen reaching $23.53 billion by 2030

The market for structural biology and molecular modeling techniques is projected to nearly double from 2025 to 2030 as drug discovery, personalized medicine and AI-driven life sciences tools accelerate demand. North America led the market in 2025, while cloud platforms, virtual screening and structure-based drug design are shaping the next phase of growth.

Why it matters: - Structural biology and molecular modeling techniques are becoming core tools in drug discovery, personalized medicine and biotechnology. - The market’s projected rise to $23.53 billion by 2030 signals sustained demand for faster and more data-driven life sciences workflows. - The shift matters for pharmaceutical companies, research institutions and developers of AI-enabled modeling software.

What happened: - The Business Research Company released its Structural Biology And Molecular Modeling Techniques Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will grow from $10.28 billion in 2025 to $12.19 billion in 2026. - The report forecasts the market will reach $23.53 billion by 2030. - North America was the largest regional market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The market’s historical growth has been supported by rising pharmaceutical research, more academic structural biology programs, wider access to protein structure databases, better computational chemistry tools and higher investment in drug discovery. - The report cites a 2026-2035 forecast period and describes a 17.9% CAGR in the forward outlook. - Demand is being driven by faster drug development, cloud-based and SaaS molecular modeling platforms, precision medicine studies, artificial intelligence in life sciences and virtual screening. - Key trends include AI-powered molecular modeling tools, cloud-based structural biology solutions, simulation and docking software, data-driven drug discovery and structure-based drug design. - Structural biology examines the three-dimensional shapes of proteins, sugars and nucleic acids. - Molecular modeling builds, visualizes and modifies those molecular structures to analyze physicochemical properties and structure-activity relationships. - Personalized medicine is a major growth driver because structural biology and molecular modeling help identify molecular targets, support drug discovery and development, predict drug-target interactions, optimize drug delivery systems and aid biomarker discovery. - In February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The report’s 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The forecast suggests structural biology and molecular modeling are moving from specialized research tools to mainstream infrastructure for life sciences R&D. - The emphasis on cloud platforms and AI points to a market shaped as much by software and data workflows as by traditional lab science. - The personalized medicine backdrop indicates the sector’s growth is tied to clinical demand, not just academic research.

What's next: - Adoption is likely to keep rising as AI, cloud computing and virtual screening become more deeply embedded in drug development. - Regional competition may widen as Asia-Pacific and other markets expand their structural biology and molecular modeling capabilities. - Companies focused on structure-based drug design and simulation software are positioned to benefit from the next wave of demand. - More information is available in the full market report and a free sample report.